Zantac (Ranitidine) Lawsuit – Cancer Risk

Popular heartburn drug Zantac (ranitidine) may be contaminated with a cancer-causing industrial chemical, NDMA (N-nitrosodimethylamine). People who were diagnosed with Bladder, Kidney, Breast, Testicular, Pediatric Testicular, or Prostate Cancer cancer may be filing Zantac and ranitidine lawsuits.

Free Case Evaluation

Zantac (Ranitidine) Cancer Lawsuit Investigation

Zantac LawsuitThe FDA recently warned that Zantac and generic or store brand ranitidine heartburn medication products may contain a cancer-causing agent NDMA (N-nitrosodimethylamine). NDMA is a chemical normally found in petroleum-based products such as gasoline, rocket fuel and industrial lubricants.

People who took prescription or over-the-counter Zantac, generic ranitidine, store brand products such as Rite Aid or CVS Acid Reducer, Walgreens Wal-Zan or other brands of Acid Reducer, Acid Controller, or Heartburn Relief products containing ranitidine and developed cancer may be filing lawsuits against Sanofi-Aventis, Zantac’s manufacturer, generic suppliers or retailers. People who may be eligible for compensation from a Zantac lawsuit include:

Those who took prescription or OTC Zantac medication regularly for at least 60 days and were diagnosed with:

  • Stomach or gastric cancer
  • Kidney cancer
  • Bladder cancer
  • Pancreatic cancer
  • Colon cancer

If cancer was diagnosed more than 6 months after Zantac (ranitidine) use was discontinued, it must have been taken regularly for more than 1 year.

The FDA has required that Sanofi recall its Zantac medications, as well as all generic manufacturers. Pharmacies including large chain drugstores and big-box stores like CVS, Walgreens, Walmart and others have pulled Zantac and store brand ranitidine products off their shelves over concerns about cancers caused by NDMA in the medications.

FDA Zantac Contamination Warning

European and U.S. health agencies including the U.S. Food and Drug Administration (FDA) are warning that popular heartburn drug Zantac, and other generic or store brand formulations of over-the-counter acid-reducers and prescription forms of ranitidine, may contain a cancer-causing agent, N-nitrosodimethylamine (NDMA).

NDMA is a semi-volatile organic compound used as a stabilizer in gasoline, rocket fuel and other petroleum-based industrial products and is a byproduct of pesticide manufacturing and other industries. NDMA is a known human carcinogen according to the U.S. Environmental Protection Agency (EPA).

NDMA is an environmental contaminant that is sometimes found in water and foods. NDMA levels in Zantac and ranitidine products have been found to be 3,000 to 26,000 times higher than legally allowed levels which were set by the FDA.

Previous NDMA Contamination of Drugs Unrelated to Zantac

Recently, other medications including the prescription high blood pressure medication, Diovan or valsartan, have been under investigation for contamination with NDMA and similar agents. The FDA has required that a number of similar Angiotensin II Receptor Blockers (ARBs) be recalled for contamination with NDMA and similar chemicals. All ARB contamination appears to have originated at pharmaceutical ingredient manufacturing plants in China and India.

This type of contamination does not appear to be related to the NDMA that is present in Zantac and ranitidine medications. Some evidence is showing that the NDMA which is appearing in Zantac may be caused by instability of the ranitidine medication itself which may lead to the formation of the carcinogen under certain manufacturing or storage conditions. Experts have also postulated that the problem may not be new but may have been partially identified in the 1980s, becoming evident now with clearer and more accurate research methods.

Zantac and Ranitidine Recalls

Sanofi-Aventis has voluntarily recalled its Zantac products and several generic ranitidine manufacturers have followed suit including Novartis-AG Sandoz, Apotex, GlaxoSmithKline and others have also issued voluntary recalls due to elevated levels of NDMA. Zantac and ranitidine have been recalled or removed from the market in multiple countries including the U.S., Canada, Hong Kong, India, Pakistan, Taiwan and countries of the EU.

In addition to manufacturer recalls, a number of pharmacies, chain drugstores and big-box stores have pulled Zantac and store-brand ranitidine or generics off of their shelves. CVS, Walgreens and Walmart are some of the notable retailers that are discontinuing Zantac and ranitidine products. The FDA has permanently discontinued all products containing ranitidine and has also asked manufacturers to quickly respond if other medications such as similar antacid medication, nizatidine, active ingredient in Axid, begin to show increased levels of NDMA.

The FDA has not recommended that people immediately discontinue taking Zantac or ranitidine but a number of health experts have noted that patients have a number of alternatives when taking medication for reflux or heartburn. Patients are advised to seek a recommendation from their healthcare practitioner before discontinuing medication.

Carcinogenic Zantac Effects

Though health experts have stated that the short-term risk of NDMA-caused cancer from medication use may be low, longer term exposure has not been fully evaluated. NDMA, however has been shown to be a potent carcinogen in other industries.

Potential carcinogenic effects of NDMA exposure include:

  • Stomach cancer
  • Bladder cancer
  • Kidney cancer
  • Intestinal cancer
  • Colon cancer
  • Pancreatic cancer

Zantac (Ranitidine) Cancer Attorneys

People who have been diagnosed or developed cancer after taking Zantac prescription or over-the-counter formulations or other medications containing ranitidine may be eligible for compensation.

Eligibility for filing a Zantac (ranitidine) lawsuit include those who used ranitidine regularly for over 60 days and were diagnosed with:

  • Stomach or gastric cancer
  • Colon or intestinal cancer
  • Bladder cancer
  • Kidney cancer
  • Pancreatic cancer

People whose cancer diagnosis occurred more than 6 months after discontinuing ranitidine use, must have taken brand-name prescription or over-the-counter Zantac or certain store brands of ranitidine regularly for more than 1 year.

Zantac (ranitidine) cancer lawsuits may provide compensation for damages including:

  • Past and future medical costs
  • Lost wages
  • Pain and suffering
  • Temporary or permanent disability
  • Punitive damages
  • Wrongful death

People or loved ones of those who may have developed cancer after using Zantac (ranitidine) should seek advice from legal experts.

Contact Seeger Weiss for a free case evaluation, or call 866-679-0650.



Since its establishment in 1999, Seeger Weiss has led some of the most complex and high-profile litigations in the U.S.